


Supplementary Figure 4



Supplementary Figure 4. On-treatment VAF was (A) not associated with baseline ECOG performance status ($p=0.23$), but (B) was significantly greater in patients with liver metastases than those without ($p=0.012$). On-treatment VAF was not related to (C) lymph node metastases ($p=0.48$), (D) line of treatment (Kruskal-Wallis $p=0.69$) or (E) smoking history ($p=0.82$). For all box plots, the horizontal bar represents the mean, the box represents the 25th and 75th percentiles, and whiskers $\pm 1.5 \times \text{IQR}$.

* $p < 0.05$